Systems biology and combination therapy in the quest for clinical efficacy
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Background
Cited by
Items 201–300 of 570
Analyzing lognormal data: A nonmathematical practical guide
Motulsky, H. J., Head, T., & Clarke, P. B. S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100049 · Cited by 41
Tempo and mode of inhibitor–mutagen antiviral therapies: A multidisciplinary approach
Iranzo, J., Perales, C., Domingo, E., & Manrubia, S. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110489108 · Cited by 37
“kγ − iG þmGð1−w0Þ iG þ γμ0=ð1−w0Þ ; [9]”
Building a drug–target network and its applications
Lee, S., Park, K., & Kim, D. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903322234 · Cited by 39
“However, such technology is still in its infancy [80-83].”
BackgroundWeiss, A., & Nowak-Sliwinska, P. M. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630316682338 · Cited by 39
“Optimized drug combinations (ODCs) may help to overcome some of the above-mentioned limitations by challenging the robustness and redundancy of biological processes.(9) Major advantages of combination therapies are based on the fact that treatment options and parameters can be “finetuned” for optimal therapy, and even…”
BackgroundHuman epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
Maria, B., Sims, A. H., & Simon, P. L. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0062 · Cited by 39
ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma
Ndoye, A., Budina-Kolomets, A., Kugel, C. H., Webster, M. R., Kaur, A., Behera, R., Rebecca, V. W., Li, L., Brafford, P. A., Liu, Q., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0907 · Cited by 37
Rani, P., Dutta, K., & Kumar, V. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105334 · Cited by 38
Bai, L., Yang, J. C., Ok, J.-H., Mack, P. C., Kung, H., & Evans, C. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26303 · Cited by 36
Searching for synergy in silico, in vitro and in vivo
Sucher, N. J. (2014) · Synergy · doi:10.1016/j.synres.2014.07.004 · Cited by 39
“[32] Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK.”
BackgroundRoller, D. G., Axelrod, M., Capaldo, B. J., Jensen, K., Mackey, A., Weber, M. J., & Gioeli, D. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0461 · Cited by 35
“org Mol Cancer Ther; 11(11) November 2012 2509”
BackgroundInfluentialLötsch, J., & Geißlinger, G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.003 · Cited by 36
Systems pharmacology-based study of Tanreqing injection in airway mucus hypersecretion
Liu, W., Zhang, X., Mao, B., & Jiang, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112425 · Cited by 35
He, H., Duo, H., Hao, Y., Zhang, X., Zhou, X., Zeng, Y., Li, Y., & Li, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106671 · Cited by 36
Kim, S., Masum, F., Kim, J.-K., Chung, H. J., & Jeon, J. S. (2019) · Lab on a Chip · doi:10.1039/c8lc01406j · Cited by 37
Rational engineering of antibody therapeutics targeting multiple oncogene pathways
Fitzgerald, J. B., & Lugovskoy, A. A. (2011) · mAbs · doi:10.4161/mabs.3.3.15299 · Cited by 35
Self-citationPsychiatric research: psychoproteomics, degradomics and systems biology
Kobeissy, F. H., Sadasivan, S., Liu, J., Gold, M. S., & Wang, K. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.293 · Cited by 34
Agoni, C., Ramharack, P., & Soliman, M. E. S. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0197 · Cited by 34
Experimental design and statistical analysis for three-drug combination studies
Fang, H., Chen, X., Pei, X., Grant, S., & Tan, M. T. (2015) · Statistical Methods in Medical Research · doi:10.1177/0962280215574320 · Cited by 34
“The sample sizes (number of experimental units) to detect a given meaningful departure ð Þ can be calculated at a given significance level ( ) and a given power level (1 ) based on the F-statistic in equation (9).”
BackgroundMethodInfluentialCampos‐Estrada, C., Liempi, A. I., González‐Herrera, F., Lapier, M., Kemmerling, U., Pesce, B., Ferreira, J., López‐Muñoz, R., & Maya, J. D. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003770 · Cited by 34
“It is possible that two drugs acting on the same target may behave as antagonistic [38,39].”
BackgroundMeasuring higher-order drug interactions: A review of recent approaches
Tekin, E., Savage, V. M., & Yeh, P. J. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.05.015 · Cited by 38
Discovery of a low order drug-cell response surface for applications in personalized medicine
Ding, X., Liu, W., Weiss, A., Li, Y., Wong, I., Griffioen, A. W., van den Bergh, H., Xu, H., Nowak-Sliwinska, P. M., & Ho, C. (2014) · Physical Biology · doi:10.1088/1478-3975/11/6/065003 · Cited by 33
OCSANA: optimal combinations of interventions from network analysis
Vera‐Licona, P., Bonnet, É., Barillot, E., & Zinovyev, A. Y. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt195 · Cited by 33
A Common Suite of Coagulation Proteins Function in Drosophila Muscle Attachment
Green, N. M., Odell, N., Zych, M. G., Clark, C. P., Wang, Z.-H., Biersmith, B. H., Bajzek, C., Cook, K. R., Dushay, M. S., & Geisbrecht, E. R. (2016) · Genetics · doi:10.1534/genetics.116.189787 · Cited by 35
“The Bliss independence testwas used to determine the expected contribution of additive phenotypes (Fitzgerald et al.2006).”
MethodHuang, H., Pan, L., Pan, S., & Song, M. (2017) · Aquaculture Research · doi:10.1111/are.13500 · Cited by 33
Liang, W., Zheng, Y., Zhang, J., & Sun, X. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2737-1 · Cited by 37
Sinzger-D’Angelo, M., Vanhoefer, J., Loos, C., & Hasenauer, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-38907-x · Cited by 35
Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine
Ho, D., Zarrinpar, A., & Chow, E. K. (2016) · ACS Nano · doi:10.1021/acsnano.6b06174 · Cited by 33
Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
Kirouac, D. C., & Onsum, M. D. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.38 · Cited by 35
“11 In addition, tumors are widely heterogeneous at the molecular level.”
BackgroundAssessment of non-linear combination effect terms for drug–drug interactions
Koch, G., Schropp, J., & Jusko, W. J. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9490-0 · Cited by 37
O'Connell, C. E., & Vassilev, A. P. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3371 · Cited by 32
“Combination therapy is a cornerstone of cancer treatment, used to prevent and overcome drug resistance, reduce adverse events by lower drug dosage, and enhance effectiveness through drug synergy (43).”
BackgroundER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
Alcon, C., Zañudo, J. G. T., Albert, R., Wagle, N., Scaltriti, M., Letai, A. G., Samitier, J., & Montero, J. (2021) · Cells · doi:10.3390/cells10071659 · Cited by 33
“These results were further corroborated by the observation of a synergistic combination (CI < 1) [39] with the sequential treatment of ipatasertib followed by A-133 in MDA-MB-415 (CI = 0.”
MethodResultIncreasing the Robustness and Validity of RNAi Screens
Haney, S. A. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1037 · Cited by 35
“This is used most frequently in transcriptional profiling data, but criteria for including other datasets, including RNAi screening data, are in discussion [10–13].”
MethodZhai, Q., Li, J., Feng, Y., & Ge, Q. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.11.065 · Cited by 31
Piao, C., Luo, J., Jin, D., Tang, C. W., Wang, L., Lian, F., & Tong, X. (2019) · Chinese Medicine · doi:10.1186/s13020-019-0280-7 · Cited by 31
Garmaroudi, F. S., Handy, D. E., Liu, Y., & Loscalzo, J. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004822 · Cited by 31
“Previous studies have used models of cell signaling networks to evaluate the action of drug pairs as compared with corresponding individual drugs [42].”
Backgroundder Borght, K. V., Tourny, A., Bagdziunas, R., Thas, O., Nazarov, M., Turner, H., Verbist, B. M. P., & Ceulemans, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-18068-5 · Cited by 33
“Scientific Reports, 7 (1), 17935-1-17935-9.”
Zhu, X., Straubinger, R. M., & Jusko, W. J. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9429-x · Cited by 33
“To evolve from the empirical model into a more mechanism-based model, data were obtained for key biomarkers of effects mediated by the combinations, and systems or network models were then applied to describe detailed signaling pathways of interactions [26, 27].”
MethodSu, J., Cheng, H., Zhang, D., Wang, M., Xie, C., Hu, Y., Chang, H. C.-W., & Li, Q. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00972 · Cited by 30
Cruickshank, M. N., Ford, J., Cheung, L. C., Heng, J., Singh, S., Wells, J. E., Failes, T. W., Arndt, G. M., Smithers, N. N., Prinjha, R. K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.165 · Cited by 34
Zhang, G., Scarborough, H. A., Kim, J., Rozhok, A. I., Chen, Y. A., Zhang, X., Song, L., Bai, Y., Fang, B., Liu, R. Z., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf5011 · Cited by 31
“Simple signaling models along with mathematical modeling have demonstrated that combination effects of hitting two proteins can be non-obvious and is a manifestation of the topology or circuitry of the signaling network (8).”
BackgroundA Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy
Zheng, Y., Bao, J., Zhao, Q., Zhou, T., & Sun, X. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0634 · Cited by 32
“To quantitatively evaluate the synergy of the CSF1R-I and IGF1R-I co-treatment, a combination index based on Bliss independence (40, 41) was defined as follows:”
MethodZhao, J., Zhang, X., & Zhang, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.79 · Cited by 32
Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations
Tang, J. P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7154-1_30 · Cited by 30
“The Bliss independence model, on the other hand, can be justified in cases where two drugs are targeting different pathways and thus elicit their effects independent of each other [69].”
BackgroundAlcon, C., Manzano-Muñoz, A., Prada, E., Mora, J., Soriano, A., Guillén, G., Gallego, S., Roma, J. M., Samitier, J., Villanueva, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02887-y · Cited by 32
Khan, I., Mahfooz, S., Faisal, M., Alatar, A. A., & Ansari, I. A. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1828942 · Cited by 29
“Combinatorial chemotherapeutic strategies, in which more than one drug is used against cancer cells is well known for its effectiveness (26).”
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov
Yang, J., Kang, H., Lyu, L., Xiong, W., & Yuanjia, H. (2023) · Discover Oncology · doi:10.1007/s12672-023-00758-4 · Cited by 35
“Combination strategies have certainly been regarded as necessary for the majority of new targeted drugs [3] and many combination therapies have shown durable responses [4].”
BackgroundYan, B., Deng, Y., Hou, J., Bi, Q., Yang, M., Jiang, B., Liu, X., Wu, W., & Guo, D. (2014) · Molecular BioSystems · doi:10.1039/c4mb00529e · Cited by 29
Bioinformatics and systems biology
Ram, P. T., Mendelsohn, J. M., & Mills, G. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.008 · Cited by 33
“Fitzgerald et al. (Fitzgerald et al., 2006) developed a computational model to estimate the dose e response of proteins inhibited with single drug or drug combinations, and predicted the potency of drugs that inhibited single enzymes, signaling pathways, and interregulated signaling cascades.”
BackgroundSeino, M., Okada, M., Sakaki, H., TAKEDA, H., WATARAI, H., Suzuki, S., Seino, S., Kuramoto, K., Ohta, T., Nagase, S., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4377 · Cited by 29
Dynamic Targeting in Cancer Treatment
Wang, Z., & Deisboeck, T. S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00096 · Cited by 31
“, combination therapy, which can potentially block these parallel or alternative pathways activated in cancer cells (Fitzgerald et al., 2006).”
BackgroundPark, M., Jin, J., An, D. Y., Kim, D.-H., Lee, J., Yun, J. W., Hwang, I., Park, J. S., Kim, M. K., Lee, Y. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3933 · Cited by 29
An engineering design approach to systems biology
Janes, K. A., Chandran, P. L., Ford, R. M., Lazzara, M. J., Papin, J. A., Peirce, S. M., Saucerman, J. J., & Lauffenburger, D. A. (2017) · Integrative Biology · doi:10.1039/c7ib00014f · Cited by 29
Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
Chen, T., Hu, Y., Liu, B., Huang, X., Li, Q., Gao, N., Jin, Z., Jia, T., Guo, D., & Jin, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.6815 · Cited by 28
“Conventional therapies involving surgery, chemotherapy, and radiation therapy are often unable to eradicate all tumor cells and hence have low rates of efficacy (3).”
Network rewiring, adaptive resistance and combating strategies in breast cancer
Cremers, C. G., & Nguyen, L. K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.60 · Cited by 38
“While it is much more costly and practically challenging to screen vast number of possible target/drug combinations experimentally, predictive modelling, in principle, can be exploited to narrow down myriad possibilities and prioritise optimal combinations, thereby focusing experimental efforts only on these lead cand…”
BackgroundShen, Y., Liu, T. “., Chen, J., Li, X., Liu, L., Shen, J., Wang, J., Zhang, R., Sun, M., Wang, Z., et al. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900114 · Cited by 28
Quantifying synergy in the bioassay-guided fractionation of natural product extracts
Dettweiler, M., Marquez, L., Bao, M., & Quave, C. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235723 · Cited by 29
“Drugs that interact synergistically in a mixture have the advantage of requiring lower doses for efficacy compared to their isolated use [6], but even in the absence of synergy, drug mixtures can exhibit lower toxicity and slow the development of resistance [7].”
BackgroundPIM kinases as therapeutic targets against advanced melanoma
Shannan, B., Watters, A. K., Chen, Q., Mollin, S., Dörr, M., Meggers, E., Xu, X., Gimotty, P. A., Perego, M., Li, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10703 · Cited by 30
“Synergy was observed for the SGI-1776 and AZD6482 combination using the Bliss formula [37]; however, this did not occur at the same doses in the two melanoma cell lines investigated (Figure 7A).”
MethodCombination therapy: Current status and future perspectives
Malik, M. A., Wani, M. Y., & Hashmi, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820576-1.00001-1 · Cited by 27
Zhang, X., Pang, W., Liu, H., & Wang, J. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28913 · Cited by 27
“Combination therapy is an efficient therapeutic strategy for cancer treatment.(11,22) Herein, we found that high concentration of lidocaine caused choriocarcinoma cell apoptosis s through lowering Bax, cleaved‐caspase‐3 and cleaved‐caspase‐9.”
BackgroundWang, A., Xu, H., & Ding, X. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900135 · Cited by 28
Enhanced stochastic optimization algorithm for finding effective multi-target therapeutics
Yoon, B.-J. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-s1-s18 · Cited by 30
“For this reason, monotherapy using a single drug that targets a specific protein (or gene) is often limited in its therapeutic effect, and multi-target therapeutics are considered to be much more effective [1-6].”
BackgroundSignaling networks in MS: A systems-based approach to developing new pharmacological therapies
Kotelnikova, E. A., Bernardo-Faura, M., Silberberg, G., Kiani, N. A., Messinis, D. E., Melas, I. N., Artigas, L., Schwartz, E., Mazo, I. A., Masso, M., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514543339 · Cited by 28
Choi, Y. S., Jang, H., Gupta, B., Jeong, J.-H., Ge, Y., Yong, C. S., Kim, J. O., Bae, J., Song, I., Kim, I., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00952-9 · Cited by 28
Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles
Gregory, J. V., Vogus, D. R., Barajas, A., Cadena, M., Mitragotri, S., & Lahann, J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000564 · Cited by 29
Dynamic Covalent Prodrug Nanonetworks via Reaction-Induced Self-Assembly for Periodontitis Treatment
Wu, H., Liu, Y., Wang, Y., Piao, Y., Meng, Z., Hu, X., Shi, L., Shen, J. Q., & Li, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c12580 · Cited by 27
As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB
Wang, P., Qu, X., Wang, X., Liu, L., Zhu, X., Zeng, H., & Zhu, H. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.10.010 · Cited by 26
Liu, J., Zhu, J., Xue, J., Qin, Z., Shen, F., Liu, J., Chen, X., Li, X., Wu, Z., Xiao, W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16571-3 · Cited by 25
Zhou, C., Wang, Q., Jin, L., Wang, R., Yin, Y., Sun, S., Zhang, J., & Wang, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.533209 · Cited by 25
Selective Control of the Apoptosis Signaling Network in Heterogeneous Cell Populations
Calzolari, D., Paternostro, G., Harrington, P. L., Piermarocchi, C., & Duxbury, P. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000547 · Cited by 25
“We introduce the concept of selective control or selectivity in cell populations as the requirement of finding a set of inputs which induce one member of the population to produce a desired response while ensuring that the remaining members of the population have a minimal response. In the case of apoptosis or cell de…”
MethodNetwork systems biology for targeted cancer therapies
Zhou, T. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10282 · Cited by 26
A High-Throughput Yeast Assay Identifies Synergistic Drug Combinations
Torres, N. P., Lee, A. Y., Giaever, G. N., Nislow, C., & Brown, G. W. (2013) · Assay and Drug Development Technologies · doi:10.1089/adt.2012.503 · Cited by 28
“The null expectation is based on the multiplicative (Bliss) model, 15,18 which states that a non-synergistic combination of drugs inhibits growth as much as the product of the inhibition caused by each drug alone.”
Imoto, H., Zhang, S., & Okada, M. (2020) · Cancers · doi:10.3390/cancers12102878 · Cited by 26
Goltsov, A., Faratian, D., Langdon, S. P., Bown, J., Goryanin, I., & Harrison, D. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.011 · Cited by 26
Peifer, M., Weiss, J. M., Sos, M. L., Koker, M., Heynck, S., Netzer, C., Fischer, S., Rode, H. B., Rauh, D., Rahnenführer, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008919 · Cited by 27
“Other approaches involving the network structure of complex biological systems have been proposed [24,35].”
BackgroundMethodKarjalainen, E., & Repasky, G. A. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.005 · Cited by 28
Khoury, M., Beyrouthy, M. E., Ouaïni, N., Éparvier, V., & Stien, D. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.01.001 · Cited by 25
177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
Hofving, T., Sandblom, V., Arvidsson, Y., Shubbar, E., Altiparmak, G., Swanpalmer, J., Almobarak, B., Elf, A., Johanson, V., Elias, E., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0509 · Cited by 24
Dynamical models of biomarkers and clinical progression for personalized medicine: The HIV context
Prague, M., Commenges, D., & Thiébaut, R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.004 · Cited by 27
Diverse array-designed modes of combination therapies in Fangjiomics
Liu, J. H., & Wang, Z. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.125 · Cited by 23
Wicha, S. G., Huisinga, W., & Kloft, C. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12197 · Cited by 23
Loo, S. Y., Syn, N. L. X., Koh, A. P.-F., Teng, J. C.-F., Deivasigamani, A., Tan, T. Z., Thike, A. A., Vali, S., Kapoor, S., Wang, X., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00635-5 · Cited by 22
In silico profiling of systemic effects of drugs to predict unexpected interactions
Yoo, S., Noh, K., Shin, M., Park, J., Lee, K.-H., Nam, H., & Lee, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-19614-5 · Cited by 23
“Next, we validated associations between pathways and our predicted phenotypes by PubMed manual curation (Supplementary Data 4).”
BackgroundInfluentialScreening drug target combinations in disease-related molecular networks
Luo, M., Jiao, J., & Wang, R. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2730-8 · Cited by 24
Åleskog, A., Norberg, M., Nygren, P., Rickardson, L., Kanduri, M., Tobin, G., Åberg, M., Gustafsson, M. G., Rosenquist, R., & Lindhagen, E. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802475295 · Cited by 22
Clarke, D. C., Morris, M. K., & Lauffenburger, D. A. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018655 · Cited by 23
“Synergistic and antagonistic relationships have been typically evaluated using methods incorporating Bliss independence or Loewe additivity, which are widely featured in drug combination studies (37).”
MethodPairwise interactions and the battle against combinatorics in multidrug therapies
Wood, K. B. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612365113 · Cited by 25
Gupta, Y. D., & Bhandary, S. (2024) · Wiley eBooks · doi:10.1002/9781394234196.ch5 · Cited by 28
Shen, J., Li, L., Yang, T., Cohen, P. S., & Sun, G. (2020) · Cancers · doi:10.3390/cancers12020436 · Cited by 24
“Most efforts of developing combination therapy rely on empirical screening [18–21], and developing rational approaches to identify effective combination therapy has been a challenge [7,22].”
BackgroundBiochemical Pathway Modeling Tools for Drug Target Detection in Cancer and Other Complex Diseases
Marín-Sanguino, A., Gupta, S. K., Voit, E. O., & Vera, J. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381270-4.00011-1 · Cited by 21
“Toward this end, the following sections define, explain, and illustrate the use of a number of computational and mathematical modeling tools that allow: (a) the detection of critical biochemical processes, whose modulation may overcome the pathological conditions under investigation; (b) the design of clinically feasi…”
BackgroundNew insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling
Erickson, K. E., Rukhlenko, O. S., Posner, R. G., Hlavacek, W. S., & Kholodenko, B. N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.008 · Cited by 19
Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers
Clarke, R. C., Tyson, J. J., Tan, M. T., Baumann, W. T., Lu, J., Xuan, J., & Wang, Y. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0309 · Cited by 23
Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging
Flusberg, D. A., & Sorger, P. K. (2013) · Physical Biology · doi:10.1088/1478-3975/10/3/035002 · Cited by 21
Self-citationKelly, P., Hadi-Nezhad, F., Liu, D. Y., Lawrence, T. J., Linington, R. G., Ibba, M., & Ardell, D. H. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007983 · Cited by 23
“141 Advances in systems biology and chemogenomics have fueled interest in combination 142 chemotherapies to benefit from synergistic drug interactions [28-31] and combat the 143 evolution of resistance [32].”
BackgroundQuebrachitol: Global Status and Basic Research
Wang, D., Zhang, S., Chang, Z., De, K., & Zuo, Z. (2017) · Natural Products and Bioprospecting · doi:10.1007/s13659-017-0120-3 · Cited by 24
Zhu, X., Sun, Z., Ma, J., Hu, B., Yu, M., Liu, X., Yang, P., Xu, Y., Ju, D., & Mu, Q. (2022) · Phytotherapy Research · doi:10.1002/ptr.7637 · Cited by 20
Modelling viral evolution and adaptation: challenges and rewards
Manrubia, S. C. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.06.006 · Cited by 21
Rashmi, S. H., Disha, K. S., Sudheesh, N. P., Karunakaran, J., Joseph, A., Jagadesh, A., & Mudgal, P. P. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10716-5 · Cited by 21
de Clare, M., & Oliver, S. G. (2013) · BMC Biology · doi:10.1186/1741-7007-11-24 · Cited by 19
“Conversely, considering pairs of genes/drugs for which the deletion mutant is resistant to treatment could assist in identifying those drug combinations which are unlikely to succeed, reducing the search space involved in an otherwise expensive combinatorial problem [49].”
BackgroundKashif, M., Andersson, C. R., Åberg, M., Nygren, P., Sjöblom, T., Hammerling, U., Larsson, R. L., & Gustafsson, M. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0430 · Cited by 20
“been explicitly ignored, for example, in the already mentioned review by Greco and colleagues (7), its importance has been acknowledged many times in the past (2, 4, 14, 15).”
BackgroundLuo, K.-W., Yue, G. G., Ko, C., Gao, S., Lee, J. K.-M., Li, G., Fung, K., Leung, P., & Lau, C. B. (2015) · Oncology Reports · doi:10.3892/or.2015.4001 · Cited by 19
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.